MADISON, Wisconsin – July 22, 2013 – DNASTAR® announced that it received a Phase II SBIR grant award from the National Institutes of Health entitled, “Association Analysis Software for Mining Clinical Next-Gen Sequencing Data”. This is the second phase of a project initially funded in 2012 to support the company’s research and development aimed at expanding its industry-leading sequence assembly and analysis software from broad research usage to the clinical research market.
Tom Schwei, Vice President and General Manager of DNASTAR, commented, “There is a growing trend to consider analyzing genomic information as part of clinical studies, whether retrospectively or prospectively. Increasingly, clinical researchers are seeing that including a genomic component to clinical research can uncover key information that is critical in moving a study forward. We are pleased to receive this funding to continue our work in adapting our general research software to the specific needs of clinical researchers. As part of this grant research program, we will be collaborating with clinicians on several cancer studies to ensure our software fully meets their needs.”
Schwei concluded, “This project ties in well with DNASTAR’s long-term strategy, which is to build on our strength in sequencing software for the general research market and expand into a wide range of related fields. Clinical research is one of those very important areas we are addressing for the future.”
DNASTAR, Inc., Madison, Wisconsin, is a pioneer in the development and sale of software used to increase life scientists’ productivity using their desktop computer or on the Amazon Cloud. DNASTAR’s comprehensive software suite, Lasergene, supports molecular biologists, geneticists, and structural biologists in meeting virtually all of their DNA, RNA, and protein sequence needs, including Sanger and next-generation sequence assembly and analysis, protein sequence and structure analysis, and protein structure prediction with easy to use, affordable, flexible computer software.
VP & General Manager
U.S. Toll Free: 866-511-5090
Research discussed in this press release will be supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R44HG006578. The content is solely the responsibility of DNASTAR and does not necessarily represent the official views of the National Institutes of Health.